Composition for treating mastitis and other staphylococcal infections
US5858962A · kind A · utility
16Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 1993 |
| Grant date | Jan 12, 1999 |
| Priority date | — |
| Expiry date | Dec 16, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/24075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lysostaphin is used to eliminate and cure staphylococcal infections including the cure of mastitis by intramammary infusion. Administration of from 2 mg to 400 mg of lysostaphin to an infected bovine mammary gland eliminates staphylococci, and the reoccurrence common with antibiotic therapy is not observed. Teat-dips containing lysostaphin, mutanolysin and lysozyme can be used as a prophylactic. Synergistic enhancement of the killing effect of lysostaphin is observed when a mild surfactant or penicillin or both is included in the formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.